Ownership and insider activity for Metagenomi, Inc. Common Stock (MGX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
Price
| Price | $1.15 |
| Market Cap | $43M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-09 | Reid Laurence | P-Purchase | 117 | $138 |
| 2026-09-09 | Reid Laurence | P-Purchase | 19,883 | $23K |
| 2026-09-08 | Wein Matthew | S-Sale | 358 | $415 |
| 2026-09-08 | Irish Jian | S-Sale | 2,140 | $2K |
| 2026-09-08 | Wapnick Pamela | S-Sale | 1,911 | $2K |
| 2026-06-09 | Reid Laurence | A-Award | 17,400 | $21K |
| 2026-06-09 | Dere Willard H | A-Award | 21,000 | $26K |
| 2026-06-09 | BJERKHOLT ERIC | A-Award | 21,000 | $26K |
| 2026-06-09 | Eckhardt Juergen | A-Award | 21,000 | $26K |
| 2026-06-05 | Wapnick Pamela | S-Sale | 2,884 | $4K |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $39.3M | $184.4M | $140.6M | $27.4M | $41.7M |
| Short-term Investments | $68.9M | $177.7M | $130.6M | $220.9M | $119.1M |
| Receivables | $490000 | $1.3M | $2.5M | $1.3M | $305000 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $108.9M | $366.9M | $278.3M | $258.0M | $165.5M |
| Property, Plant & Equipment | $22.1M | $33.3M | $65.2M | $57.7M | $47.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $142.0M | $414.5M | $364.8M | $324.6M | $221.1M |
| Accounts Payable | $1.4M | $2.0M | $1.8M | $533000 | $1.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $25.2M | $48.5M | $68.9M | $37.3M | $22.9M |
| Long-term Debt | $30.3M | 0 | 0 | 0 | 0 |
| Total Liabilities | $174.5M | $488.9M | $500.4M | $89.7M | $62.5M |
| Retained Earnings | -$33.1M | -$76.7M | -$144.9M | -$223.0M | -$310.9M |
| Total Equity | -$32.5M | -$74.4M | -$135.6M | $234.9M | $158.6M |
| Total Debt | $48.9M | $18.6M | $48.2M | $45.8M | $40.7M |
| Net Debt | -$59.2M | -$343.6M | -$223.0M | -$202.5M | -$120.1M |
| Working Capital | $83.7M | $318.4M | $209.4M | $220.7M | $142.6M |
Financial Health
| Debt / Equity | 0.34 |
| Current Ratio | 4.50 |
Profitability
| Return on Equity | -63.65% |
| Return on Invested Capital | -65.88% |
| Return on Assets | -53.81% |
| Gross Margin | 74.29% |
| Operating Margin | -741.58% |
| Net Margin | -689.20% |
Related companies: ADVM · ALXO · ARTV · ATYR · CNTB · DTIL · IFRX
Explore sector: Healthcare · Biotechnology
More sections of MGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks